<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626492</url>
  </required_header>
  <id_info>
    <org_study_id>ZDWY.FSK.005</org_study_id>
    <nct_id>NCT04626492</nct_id>
  </id_info>
  <brief_title>Quantitative MRI Imaging in Diffuse Liver Diseases</brief_title>
  <acronym>QMIDLD</acronym>
  <official_title>Clinical Study on the Value of Quantitative MRI Imaging in Diffuse Liver Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fifth Affiliated Hospital, Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      As we all know, the early diagnosis and accurate staging of liver fibrosis are very important&#xD;
      to reduce the incidence of liver cirrhosis and liver cancer. And the accurate evaluation of&#xD;
      hepatic fibrosis is of great significance to the prediction of residual liver function after&#xD;
      liver surgery. Therefore, clinicians pay more and more attention to the qualitative and&#xD;
      quantitative diagnosis of hepatic fibrosis, liver cirrhosis and hepatic steatosis involved in&#xD;
      diffuse liver diseases(such as fatty liver, viral hepatitis, autoimmune hepatitis ). And now,&#xD;
      liver biopsy is commonly used as the gold standard for the evaluation of steatohepatitis and&#xD;
      fibrosis. However, this test is invasive, has low patient acceptance. So more and more&#xD;
      clinicians recommend non-invasive methods to qualitatively and quantitatively evaluate the&#xD;
      liver steatosis, fibrosis and cirrhosis in diffuse liver diseases. At present, serum markers,&#xD;
      ultrasonic elastography and magnetic resonance imaging have good accuracy in the non-invasive&#xD;
      detection and evaluation of liver cirrhosis. However, serum markers are not liver-specific,&#xD;
      and a single serum marker is not enough to accurately reflect the degree of liver fibrosis.&#xD;
      Furthermore, whether the non-invasive liver fiber diagnostic model is suitable for patients&#xD;
      with liver disease in China remains to be further verified. At present, transient&#xD;
      elastography has been recommended for the non-invasive staging of hepatic fibrosis by the&#xD;
      clinical practice guidelines of the European Association for liver Research and the&#xD;
      Asia-Pacific Association for liver Research. But as serum markers, it still has low&#xD;
      sensitivity and specificity in the diagnosis of early hepatic fibrosis, and is highly&#xD;
      operationally dependent. With the development of MRI technology, some MRI quantitative&#xD;
      techniques, such as T1mapping, T2mapping,Intravoxel incoherent motion diffusion-weighted&#xD;
      magnetic resonance imaging(IVIM-DWI), dynamic contrast enhanced magnetic resonance&#xD;
      imaging(DCE-MRI) can be used to qualitatively and quantitatively diagnosis of liver fat,&#xD;
      hepatic fibrosis and cirrhosis. And iterative decomposition of water and fat with echo&#xD;
      asymmetry and least squares estimation quantification sequence(IDEALIQ) usually used to&#xD;
      evaluate liver fat. The existing research results showed that MRI quantitative techniques has&#xD;
      a high value in quantitative diagnosis of advanced hepatic fibrosis and cirrhosis. But it&#xD;
      still has some limitations in quantitative diagnosis of early liver fibrosis. And what's&#xD;
      more,some of the research results still can not reach a consensus. Therefore, based on the&#xD;
      multi-parameter potential of MRI and the characteristics of metabolic evaluation. This study&#xD;
      will adjust some of the parameters of MRI quantitative techniques, and through large sample&#xD;
      datas, combined with a variety of quantitative techniques to explore the application value of&#xD;
      MRI quantitative techniques in the quantitative diagnosis of liver diffuse lesions,&#xD;
      especially in the early stage of liver fibrosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Quantitative MRI imaging diagnose diffuse hepatic lesions</measure>
    <time_frame>2 years</time_frame>
    <description>Quantitative MRI imaging(such as dynamic contrast enhanced magnetic, intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging resonance imaging, Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging, Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence) used to quantitative diagnosis of fatty liver hepatitis, liver fibrosis, cirrhosis, etc.</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fibrosis and Cirrhosis of Liver</condition>
  <arm_group>
    <arm_group_label>F0</arm_group_label>
    <description>Normal control group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F1</arm_group_label>
    <description>Grade 1 of liver fibrosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F2</arm_group_label>
    <description>Grade 2 of liver fibrosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F3</arm_group_label>
    <description>Grade 3 of liver fibrosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F4</arm_group_label>
    <description>Hepatic cirrhosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Quantitative MRI imaging</intervention_name>
    <description>Dynamic contrast enhanced magnetic resonance imaging,Intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging,Iterative decomposition of water and fat with echo asymmetry and least squares estimation quantification sequence</description>
    <arm_group_label>F0</arm_group_label>
    <arm_group_label>F1</arm_group_label>
    <arm_group_label>F2</arm_group_label>
    <arm_group_label>F3</arm_group_label>
    <arm_group_label>F4</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Such as blood routine,liver function and liver enzyme,renal function, serous markers of liver&#xD;
      fibrosis,blood lipid,indicators related to hepatitis virus infection,emergency&#xD;
      biochemistry,etc.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All suspected patients with diffuse liver diseases meet the inclusion criteria will include&#xD;
        in this study. And patients who meet the criteria of the normal control group will include&#xD;
        in this study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Selection criteria for case group (F1-F4) (meet all the following 1-5 criteria can be&#xD;
        selected or only meet the 6 criteria)&#xD;
&#xD;
          1. Fatty liver, liver fibrosis or cirrhosis confirmed by clinical, biochemical, imaging&#xD;
             examination and liver biopsy;&#xD;
&#xD;
          2. no secondary portal hypertension and increase alpha feto protein(AFP);&#xD;
&#xD;
          3. no thrombus or plaque in the portal vein and abdominal aorta;&#xD;
&#xD;
          4. no history of psychotropic drug addiction;&#xD;
&#xD;
          5. MRI examination three days before liver puncture or liver transplantation;&#xD;
&#xD;
          6. isolated liver of patients undergoing liver transplantation.&#xD;
&#xD;
        The selection criteria of the normal control group (F0) (meet all the following 1-4&#xD;
        criteria can be selected or only meet the 5 criteria):&#xD;
&#xD;
          1. no known acute or chronic liver disease (serologically negative);&#xD;
&#xD;
          2. no history of alcoholism, and normal liver function tests;&#xD;
&#xD;
          3. no signs of chronic liver disease in CT or MRI;&#xD;
&#xD;
          4. no CT or MRI manifestations of focal or diffuse liver disease in the liver;&#xD;
&#xD;
          5. abandoned donor liver&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. contraindications for MRI or patients' inability to cooperate with MRI;&#xD;
&#xD;
          2. allergy to contrast media and poor image quality can not meet the needs of clinical&#xD;
             diagnosis;&#xD;
&#xD;
          3. less than 18 years of age, poor quality of liver biopsy;&#xD;
&#xD;
          4. renal insufficiency (eGFP &lt; 60ml/min/1.73mm2);&#xD;
&#xD;
          5. with severe heart, brain, lung and blood system diseases.&#xD;
&#xD;
          6. liver complicated with fulminant liver failure and gastrointestinal bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaolin Li, Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radiology Department，the Fifth Affiliated Hospital of Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yujuan Qin, Master</last_name>
    <phone>0086 756 2528321</phone>
    <email>qinyj5@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shaolin Li, Director</last_name>
    <phone>0086 756 2528321</phone>
    <email>lishaolin1963@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>52 Meihua East Road, New Xiangzhou</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <zip>519000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yujuan Qin, Master</last_name>
      <phone>0086 756 2528321</phone>
      <email>qinyj5@mail.sysu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Shaolin Li, Doctor</last_name>
      <phone>0086 756 2528321</phone>
      <email>lishaolin1963@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shaolin Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017 Oct;67(4):862-873. doi: 10.1016/j.jhep.2017.06.003. Epub 2017 Jun 19. Review.</citation>
    <PMID>28642059</PMID>
  </reference>
  <reference>
    <citation>Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic Steatohepatitis: A Review. JAMA. 2020 Mar 24;323(12):1175-1183. doi: 10.1001/jama.2020.2298. Review. Erratum in: JAMA. 2020 Apr 28;323(16):1619.</citation>
    <PMID>32207804</PMID>
  </reference>
  <reference>
    <citation>Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011 Jun;9(6):524-530.e1; quiz e60. doi: 10.1016/j.cgh.2011.03.020. Epub 2011 Mar 25.</citation>
    <PMID>21440669</PMID>
  </reference>
  <reference>
    <citation>Poynard T, Lenaour G, Vaillant JC, Capron F, Munteanu M, Eyraud D, Ngo Y, M'Kada H, Ratziu V, Hannoun L, Charlotte F. Liver biopsy analysis has a low level of performance for diagnosis of intermediate stages of fibrosis. Clin Gastroenterol Hepatol. 2012 Jun;10(6):657-63.e7. doi: 10.1016/j.cgh.2012.01.023. Epub 2012 Feb 14.</citation>
    <PMID>22343514</PMID>
  </reference>
  <reference>
    <citation>Dong XQ, Wu Z, Zhao H, Wang GQ; China HepB-Related Fibrosis Assessment Research Group. Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients. J Viral Hepat. 2019 Feb;26(2):297-307. doi: 10.1111/jvh.13031. Epub 2018 Nov 28.</citation>
    <PMID>30380170</PMID>
  </reference>
  <reference>
    <citation>Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003 Aug;38(2):518-26.</citation>
    <PMID>12883497</PMID>
  </reference>
  <reference>
    <citation>Thiele M, Detlefsen S, Sevelsted Møller L, Madsen BS, Fuglsang Hansen J, Fialla AD, Trebicka J, Krag A. Transient and 2-Dimensional Shear-Wave Elastography Provide Comparable Assessment of Alcoholic Liver Fibrosis and Cirrhosis. Gastroenterology. 2016 Jan;150(1):123-33. doi: 10.1053/j.gastro.2015.09.040. Epub 2015 Oct 3.</citation>
    <PMID>26435270</PMID>
  </reference>
  <reference>
    <citation>Wu S, Yang Z, Zhou J, Zeng N, He Z, Zhan S, Jia J, You H. Systematic review: diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis. Hepatol Int. 2019 Jan;13(1):91-101. doi: 10.1007/s12072-018-9907-5. Epub 2018 Nov 15.</citation>
    <PMID>30443702</PMID>
  </reference>
  <reference>
    <citation>Zhang YN, Fowler KJ, Hamilton G, Cui JY, Sy EZ, Balanay M, Hooker JC, Szeverenyi N, Sirlin CB. Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol. 2018 Sep;91(1089):20170959. doi: 10.1259/bjr.20170959. Epub 2018 Jun 6. Review.</citation>
    <PMID>29722568</PMID>
  </reference>
  <reference>
    <citation>Singh S, Venkatesh SK, Wang Z, Miller FH, Motosugi U, Low RN, Hassanein T, Asbach P, Godfrey EM, Yin M, Chen J, Keaveny AP, Bridges M, Bohte A, Murad MH, Lomas DJ, Talwalkar JA, Ehman RL. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015 Mar;13(3):440-451.e6. doi: 10.1016/j.cgh.2014.09.046. Epub 2014 Nov 20. Review.</citation>
    <PMID>25305349</PMID>
  </reference>
  <reference>
    <citation>Li Z, Sun J, Chen L, Huang N, Hu P, Hu X, Han G, Zhou Y, Bai W, Niu T, Yang X. Assessment of liver fibrosis using pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging. J Magn Reson Imaging. 2016 Jul;44(1):98-104. doi: 10.1002/jmri.25132. Epub 2015 Dec 28.</citation>
    <PMID>26707910</PMID>
  </reference>
  <reference>
    <citation>Wu CH, Ho MC, Jeng YM, Liang PC, Hu RH, Lai HS, Shih TT. Assessing hepatic fibrosis: comparing the intravoxel incoherent motion in MRI with acoustic radiation force impulse imaging in US. Eur Radiol. 2015 Dec;25(12):3552-9. doi: 10.1007/s00330-015-3774-4. Epub 2015 May 20.</citation>
    <PMID>25991478</PMID>
  </reference>
  <reference>
    <citation>Li J, Liu H, Zhang C, Yang S, Wang Y, Chen W, Li X, Wang D. Native T1 mapping compared to ultrasound elastography for staging and monitoring liver fibrosis: an animal study of repeatability, reproducibility, and accuracy. Eur Radiol. 2020 Jan;30(1):337-345. doi: 10.1007/s00330-019-06335-0. Epub 2019 Jul 23.</citation>
    <PMID>31338650</PMID>
  </reference>
  <reference>
    <citation>Hoffman DH, Ayoola A, Nickel D, Han F, Chandarana H, Shanbhogue KP. T1 mapping, T2 mapping and MR elastography of the liver for detection and staging of liver fibrosis. Abdom Radiol (NY). 2020 Mar;45(3):692-700. doi: 10.1007/s00261-019-02382-9.</citation>
    <PMID>31875241</PMID>
  </reference>
  <reference>
    <citation>Loomba R, Neuschwander-Tetri BA, Sanyal A, Chalasani N, Diehl AM, Terrault N, Kowdley K, Dasarathy S, Kleiner D, Behling C, Lavine J, Van Natta M, Middleton M, Tonascia J, Sirlin C; NASH Clinical Research Network. Multicenter Validation of Association Between Decline in MRI-PDFF and Histologic Response in NASH. Hepatology. 2020 Oct;72(4):1219-1229. doi: 10.1002/hep.31121. Epub 2020 Oct 9.</citation>
    <PMID>31965579</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fifth Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>ShaoLin Li</investigator_full_name>
    <investigator_title>Director of Radiology Department</investigator_title>
  </responsible_party>
  <keyword>Magnetic resonance imaging</keyword>
  <keyword>Fatty liver</keyword>
  <keyword>Liver Steatosis</keyword>
  <keyword>Steatohepatitis</keyword>
  <keyword>Liver Fibrosis</keyword>
  <keyword>Hepatic Cirrhosis</keyword>
  <keyword>Dynamic contrast enhanced magnetic resonance imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

